Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice

Yutao Xia, Mingfang Wang, Taosheng Huang, Kai Sun, Peng Wang · 2026

Read Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice by Yutao Xia, Mingfang Wang, Taosheng Huang, Kai Sun, Peng Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13555379.txt.

Description

A stomach-lining protein has become one of the hottest targets in oncology, and the drugs aimed at it are now meeting resistance. Yutao Xia and co-authors organize that resistance in a 2026 review. The first antibody against the target won approval in 2024, and over a hundred trials of related agents are running.

The review sorts resistance into six biological dimensions, separating tricks specific to this target from generic escape routes. Each mechanism is paired with a countermeasure, graded by the strength of its evidence. The authors argue that target levels erode under treatment pressure, so therapy sequencing matters. For patients starting with high, uniform expression, they favor an intensive induction followed by maintenance over endless combination therapy.

Catalog record

CREATORYutao Xia, Mingfang Wang, Taosheng Huang, Kai Sun, Peng Wang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13555379

Browse the full library · About the Tower of Babel